Show source-provided references
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21492 ↗2. Pfeffer, C.M., and Singh, A.T.K. (2018). Apoptosis: A Target for Anticancer Therapy. Int. J. Mol. Sci., 19.
10.3390/ijms19020448 ↗6. Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
10.2147/IJN.S289443 ↗7. Principles of nanoparticle design for overcoming biological barriers to drug delivery
10.1038/nbt.3330 ↗11. Andronescu, E., and Grumezescu, A.M. (2017). Nanostructures for Oral Medicine, Elsevier.
14. Zhang, M., Zhu, J., Zheng, Y., Guo, R., Wang, S., Mignani, S., Caminade, A.M., Majoral, J.P., and Shi, X. (2018). Doxorubicin-Conjugated PAMAM Dendrimers for pH-Responsive Drug Release and Folic Acid-Targeted Cancer Therapy. Pharmaceutics, 10.
10.3390/pharmaceutics10030162 ↗15. Docetaxel-loaded PAMAM-based poly (γ-benzyl-l-glutamate)-b-d-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles in human breast cancer and human cervical cancer therapy
16. Boisguérin, P., Konate, K., Josse, E., Vivès, E., and Deshayes, S. (2021). Peptide-Based Nanoparticles for Therapeutic Nucleic Acid Delivery. Biomedicines, 9.
10.3390/biomedicines9050583 ↗17. Neves, A.R., Albuquerque, T., Faria, R., Gonçalves, A.M., Santos, C., Vivès, E., Boisguérin, P., Passarinha, L.A., Sousa, Â., and Costa, D. (2022). Development of WRAP5 Peptide Complexes for Targeted Drug/Gene Co-Delivery toward Glioblastoma Therapy. Pharmaceutics, 14.
10.3390/pharmaceutics14102213 ↗18. Cell-Penetrating Peptide and α-Tocopherol-Conjugated Poly(amidoamine) Dendrimers for Improved Delivery and Anticancer Activity of Loaded Paclitaxel
10.1021/acsabm.0c00179 ↗20. Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial
10.1002/cam4.3056 ↗21. A randomized phase II trial of induction chemotherapy followed by cisplatin chronotherapy versus constant rate delivery combined with radiotherapy
10.1080/07420528.2017.1397684 ↗26. Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling
10.1158/1535-7163.MCT-15-0129 ↗27. Albuquerque, T., Neves, A.R., Quintela, T., and Costa, D. (2022). The Influence of Circadian Rhythm on Cancer Cells Targeting and Transfection Efficiency of a Polycation-Drug/Gene Delivery Vector. Polymers, 14.
10.3390/polym14040681 ↗28. PAMAM Dendrimer-Based Multifunctional Conjugate for Cancer Therapy: Synthesis, Characterization, and Functionality
10.1021/bm0506142 ↗29. Dendritic polyglycerol sulfate as a novel platform for paclitaxel delivery: Pitfalls of ester linkage
10.1039/C4NR04428B ↗30. Hypoxia alleviating platinum(IV)/chlorin e6-based combination chemotherapeutic-photodynamic nanomedicine for oropharyngeal carcinoma
10.1016/j.jphotobiol.2022.112627 ↗31. Dual peptide conjugation strategy for improved cellular uptake and mitochondria targeting
10.1021/bc500408p ↗32. Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumour-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer
33. Oleanolic acid-conjugated human serum albumin nanoparticles encapsulating doxorubicin as synergistic combination chemotherapy in oropharyngeal carcinoma and melanoma
10.1016/j.ijpharm.2022.121479 ↗34. Neves, A.R., Albuquerque, T., Faria, R., Paul, M., Biswas, S., Sousa, Â., and Costa, D. (2021). Development of Tailor-Made Dendrimer Ternary Complexes for Drug/Gene Co-Delivery in Cancer. Pharmaceutics, 13.
10.3390/pharmaceutics13081256 ↗35. Ferreira, M., Gomes, D., Neto, M., Passarinha, L.A., Costa, D., and Sousa, Â. (2023). Development and Characterization of Quercetin-Loaded Delivery Systems for Increasing Its Bioavailability in Cervical Cancer Cells. Pharmaceutics, 15.
10.3390/pharmaceutics15030936 ↗36. Vuelta, E., Ordonez, J., Alonso Pérez, V., Mendez, L., Hernández-Carabias, P., Saldana, R., Sevilla, J., Sebastian, E., Muntion, S., and Sanchez-Guijo, F. (2020). CRISPR/Cas9 technology abolishes the BCR/ABL1 oncogene effect in chronic myeloid leukemia and restores normal hematopoiesis. bioRxiv, 103–112.
10.1101/2020.08.05.237610 ↗37. Cathepsin B-responsive and gadolinium-labeled branched glycopolymer-PTX conjugate-derived nanotheranostics for cancer treatment
10.1016/j.apsb.2020.07.023 ↗38. Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel
10.21873/anticanres.11289 ↗39. Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis
10.2147/IJN.S290731 ↗40. Nawara, H.M., Afify, S.M., Hassan, G., Zahra, M.H., Seno, A., and Seno, M. (2021). Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy. Biomedicines, 9.
10.3390/biomedicines9050500 ↗41. Mudalige, T., Qu, H., Haute, D., Ansar, S., Paredes, A., and Ingle, T. (2019). Nanomaterials for Food Applications, Elsevier.
44. Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: In vitro and in vivo evaluation
10.1016/j.ijpharm.2016.11.047 ↗45. García-Tuñón, I., Vuelta, E., Pérez-Ramos, S., Hernández, J., Méndez, L., Herrero, M., and Sanchez-Martin, M. (2018). Modulating Gene Expression-Abridging the RNAi and CRISPR-Cas9 Technologies, Intechopen.
46. The times they’re a-changing: Effects of circadian desynchronization on physiology and disease
47. The Circadian Clock Gene Bmal1 Controls Intestinal Exporter MRP2 and Drug Disposition
10.7150/thno.33395 ↗48. CLOCK and BMAL1 regulate MyoD and are necessary for maintenance of skeletal muscle phenotype and function
10.1073/pnas.1014523107 ↗53. Lossi, L., Castagna, C., and Merighi, A. (2018). Caspase-3 Mediated Cell Death in the Normal Development of the Mammalian Cerebellum. Int. J. Mol. Sci., 19.
10.20944/preprints201811.0592.v1 ↗55. Apoptosis induced by paclitaxel via Bcl-2, Bax and caspases 3 and 9 activation in NB4 human leukaemia cells is not modulated by ERK inhibition
56. Miller, A.V., Hicks, M.A., Nakajima, W., Richardson, A.C., Windle, J.J., and Harada, H. (2013). Paclitaxel-Induced Apoptosis Is BAK-Dependent, but BAX and BIM-Independent in Breast Tumor. PLoS ONE, 8.
10.1371/journal.pone.0060685 ↗57. A novel synergistic anticancer effect of fungal cholestanol glucoside and paclitaxel: Apoptosis induced by an intrinsic pathway through ROS generation in cervical cancer cell line (HeLa)
10.1016/j.tiv.2021.105079 ↗59. Substantial cell apoptosis provoked by naked PAMAM dendrimers in HER2-positive human breast cancer via JNK and ERK1/ERK2 signalling pathways
10.1016/j.csbj.2021.05.011 ↗60. Time-of-day specificity of anticancer drugs may be mediated by circadian regulation of the cell cycle
10.1126/sciadv.abd2645 ↗61. The Circadian Gene Clock Plays an Important Role in Cell Apoptosis and the DNA Damage Response In Vitro
10.1177/1533034615585433 ↗63. Gwon, D.H., Lee, W.Y., Shin, N., Kim, S.I., Jeong, K., Lee, W.H., Kim, D.W., Hong, J., and Lee, S.Y. (2020). BMAL1 Suppresses Proliferation, Migration, and Invasion of U87MG Cells by Downregulating Cyclin B1, Phospho-AKT, and Metalloproteinase-9. Int. J. Mol. Sci., 21.
10.3390/ijms21072352 ↗64. Circadian Clock Gene Bmal1 Inhibits Tumorigenesis and Increases Paclitaxel Sensitivity in Tongue Squamous Cell Carcinoma
10.1158/0008-5472.CAN-16-1322 ↗65. Circadian clock gene BMAL1 inhibits the proliferation and tumor-formation ability of nasopharyngeal carcinoma cells and increases the sensitivity of radiotherapy
10.1080/07420528.2022.2105708 ↗67. Circadian regulator BMAL1::CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle
10.1073/pnas.2214829120 ↗68. The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma
10.1002/ijc.27598 ↗